Apotex recalls hypertension capsules that may be empty; Tobacco gets bioengineered;

> Apotex, is voluntarily recalling Lot JR2178 of hypertension drug Apo-Ramipril 5-mg capsules because some of the capsules are empty. Story

> Inserogen, a startup formed by a Ph.D. from the Universtiy of California-Davis, intends to use its "SwiftVax" plants to turn tobacco into cheap biological factories for bioengineered proteins. Story

> A survey of U.S. and EU pharmaceutical executives found a significant number who believe that "the business model is broken" and needs to be addressed by redeploying resources. Release

Suggested Articles

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.

Boehringer Ingelheim is investing $50 million in an animal health plant in Puerto Rico, adding 105 jobs.

Teva will begin producing chemo drug vincristine in the U.S. but has resisted the idea that its withdrawal from the market led to a shortage.